详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

2| 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Beijing InnoCare Pharma Tech Co., Ltd. [2]Beijing Cancer Hospital Beijing, Beijing, China, 100143 [3]Tumor in Hunan Province Hunan, Changsha, China, 410013 [4]The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China, 361003 [5]Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060 [6]Guangzhou First People's Hospital Guangzhou, Guangdong, China, 510180 [7]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 50011 [8]Henan Tumor Hospital Zhengzhou, Henan, China, 450008 [9]The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China, 450052 [10]Wuhan Union Hospital Wuhan, Hubei, China, 430022 [11]Jiangsu Province Hospital Nanjing, Jiangsu, China, 210029 [12]The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China, 215006 [13]The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China, 3300008 [14]The First Hospital of Jilin University Changchun, Jilin, China, 130021 [15]The First Hospital of China Medical University Shenyang, Liaojing, China, 110001 [16]The First Affiliated Hospital of Guangxi Medical University Guangxi, Nanning, China, 530021 [17]Shandong Provincial Hospital Jinan, Shandong, China, 250021 [18]West China Hospital,Sichuan University Chengdu, Sichuan, China, 610041 [19]Hospital of Hematology, Chinese Academy of Medical Sciences Tianjin, Tianjin, China, 300052 [20]Tianjin Cancer Hospital Tianjin, Tianjin, China, 300060 [21]he First Affiliated Hospital of Zhengjiang University Hangzhou, Zhejiang, China, 310003 [22]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310022 [23]Anhui Province Cancer Hospital Hefei, Anhui, China, 230009

研究目的：

To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the treatment of treatment-naїve mantle cell lymphoma.